Organization
Hospital Universitario Central de Asturias
4 abstracts
Abstract
177Lu-edotreotide versus everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin: The phase 3 randomized LEVEL, GETNE-T2217 trial.Org: Imas12, UCM, Hospital Universitario Central de Asturias, ISPA, University Clinical Hospital of Santiago de Compostela,
Abstract
Progression-free survival as a surrogate endpoint of overall survival in advanced biliary tract cancer: A meta-analysis of randomized trials and individual-patient level correlation.Org: Vall d'Hebron Institute of Oncology, UGC Oncología Guipúzcoa, Hospital 12 de Octubre, Hospital Universitario Central de Asturias, Hospital Universitario Gregorio Marañón,
Abstract
Spatially resolved multi-region transcriptomic subtyping and assessment of gene expression profiles associated with long-term benefit from chemo-immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).Org: Hospital Universitario 12 de Octubre, Hospital Teresa Herrera-Materno Infantil, Complejo Hospitalario Universitario A Coruna, Hospital Universitario Regional Málaga, Fundacion Jimenez Diaz University Hospital,
Abstract
A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.Org: University of Alabama at Birmingham Department of Hematology, Birmingham, AL, Bon Secours St Francis Health System, University General Hospital Attikon, University Hospitals Seidman Cancer Center, CHU Angers,